Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642951 | 0.88 | F10 (0.55) | F10CHRNA7PRMT5ACKR3F2 | |
| SCHEMBL5638163 | 0.87 | F10 (0.51) | F10ACKR3F2 | |
| SCHEMBL4593972 | 0.85 | F10 (0.53) | F10F2 | |
| SCHEMBL5638156 | 0.85 | HDAC3 (0.44) | F10CHRNA7HDAC3HDAC4HDAC1 | |
| SCHEMBL5640463 | 0.84 | CHRNA7 (0.40) | F10CHRNA7HDAC3HDAC4HDAC1 | |
| SCHEMBL5640687 | 0.84 | F10 (0.61) | F10F2 | |
| SCHEMBL4587679 | 0.83 | F10 (0.73) | F10F2 | |
| SCHEMBL4587228 | 0.82 | F10 (0.67) | F10F2 | |
| SCHEMBL8219680 | 0.82 | F10 (0.67) | F10F2 | |
| SCHEMBL4586271 | 0.82 | F10 (0.51) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | F10 18/4885HPGDS 2103/4885CHRNA7 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.